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Fragile X syndrome is the most common inherited form of mental retardation. It is caused by expansion of a trinucleotide
(CGG)n repeat sequence in the 5¢ untranslated region of the FMR1 gene, resulting in promoter hypermethylation and
suppression of FMR1 transcription. Additionally, pre-mutation alleles in carrier males and females may result in Fragile X tremor
ataxia syndrome and primary ovarian insufficiency, respectively. Fragile X is one of the most commonly requested molecular
genetic tests worldwide. Quality assessment schemes have identified a wide disparity in allele sizing between laboratories.
It is therefore important that clinical laboratories have access to characterized reference materials (RMs) to aid accurate allele
sizing and diagnosis. With this in mind, a panel of genotyping RMs for Fragile X syndrome has been developed, which should be
stable over many years and available to all diagnostic laboratories. Immortalized cell lines were produced by Epstein–Barr virus
transformation of lymphocytes from consenting patients. Genomic DNA was extracted in bulk and RM aliquots were freeze-dried
in glass ampoules. Twenty-one laboratories from seventeen countries participated in a collaborative study to assess their
suitability. Participants evaluated the samples (blinded, in triplicate) in their routine methods alongside in-house and
commercial controls. The panel of five genomic DNA samples was endorsed by the European Society of Human Genetics and
approved as an International Standard by the Expert Committee on Biological Standardization at the World Health Organization.
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INTRODUCTION
Fragile X syndrome is the most common heritable cause of mental
retardation, affecting approximately 1 in 5000 males and 1 in 10 000
females. It is caused by the expansion of a tract of CGG repeats
in the 5¢-untranslated region of the Fragile X mental retardation 1
(FMR1) gene located at Xq27.3, with consequent hypermethylation
of promotor regions and silencing of gene expression.1 As the
phenotypic presentation and frequency of clinical signs are variable,
clinical diagnosis is challenging, and definitive diagnosis in suspected
individuals requires molecular measurement of the (CGG)n allele
size. The size of the (CGG)n repeat tract is highly polymorphic
in the general population, containing from 6 to about 50 repeats and
most commonly 29–30 repeats.2–4 Individuals with alleles of 59–200
repeats, known as pre-mutations, are considered to be carriers, as alleles
of this length are highly unstable in maternal transmission and are at
very high risk of expansion into ‘full mutation’ alleles of4200 repeats,
which are causative of the Fragile X syndrome.
Selected screening is highly justified among mentally retarded
individuals, not only to provide the benefits of early clinical
intervention but also to enable prenatal diagnosis to be offered to
related carriers.5,6 Genetic testing for Fragile X syndrome is wide-
spread, but it has been acknowledged by leading laboratories in the
field to be one of the most technically challenging genetic tests.
Performance in proficiency testing has been shown to be sub-optimal
in several EQA schemes.7,8 Any assay using PCR amplification to
determine (CGG)n must overcome the problem of amplifying long
sections of repetitive CG-rich sequence. Validation of the assays used is
difficult because of the lack of reliable reference materials (RMs).
Accurate allele sizing becomes essential when distinguishing between
alleles around the normal/pre-mutation and pre-mutation/full muta-
tion thresholds. Most laboratories use DNA samples from patients
who have been characterized by their own laboratory as controls. As
such, allele sizing accuracy may vary between laboratories. Labora-
tories that are new to the field often rely on small finite amounts of
materials supplied by other genetic reference laboratories, for example
as part of external quality assessment schemes. However, these
control materials are in short supply because of the relatively large
amount needed for investigation (by Southern blotting) and sample
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distribution restrictions in Europe imposed by the IVD Directive
(Directive 98/79/EC of the European Parliament and of the Council of 27
October 1998 on in vitro diagnostic medical devices).
The high frequency of male and female carriers of FMR1 pre-
mutation alleles (B1/813–1/251 andB1/259–1/113, respectively,)9–13
and the occurrence of pre-mutation phenotypes such as Fragile X
tremor ataxia syndrome (FXTAS)14 and Fragile X-associated primary
ovarian insufficiency (FXPOI)15 will doubtless lead to increased
FMR1 genotyping and possibly to screening of the general population.
The case for certified RMs to aid accuracy in FMR1 genotyping is
therefore increasing in strength.
There are no internationally certified genetic RMs available for
in vitro diagnosis of Fragile X syndrome. A panel of nine PCR
amplicons with a variety of FMR1 trinucleotide repeat length
standards is available from the US National Institute of Standards
and Technology (NIST). However, the panel does not contain any
full mutations and the materials can only be used in PCR and not in
the more definitive Southern blot assay. Genomic DNA (gDNA) RMs
would be preferable as these more closely resemble patient specimens.
Well-characterized genomic DNA materials are available from
Coriell Cell Repositories but are not approved or intended for
in vitro diagnostic use.16 Furthermore, there may be differences in
DNA quality and performance (and also possibly even differences in
allele sizes due to somatic cell mutation17 (also, KEW and JRH,
unpublished data)) in future batches.
We have therefore chosen to produce in bulk a panel of gDNA
materials that could be certified and, when eventually required, can be
replenished from the same source. Bulk genomic DNA was extracted
from immortalized cell lines produced by Epstein–Barr virus (EBV)
transformation of lymphocytes from donors who were known to carry
the wild type, pre-mutation and full mutation genotypes. Following
validation by an international collaborative study, a panel of five
gDNAs was endorsed by the European Society of Human Genetics and
then approved as an International Standard by the Expert Committee
on Biological Standardization at the World Health Organization
(WHO) in November 2008.
MATERIALS AND METHODS
Patients and cell lines
A protocol for approaching patients, obtaining informed consent and anon-
ymizing samples was approved by a local research ethics committee. Patient
blood samples were collected from six consenting donors as part of ‘CRMGEN’,
an EU 5th framework project to evaluate and develop certified RMs for genetic
testing. One donor was a normal female individual and the remainder had been
identified after previous molecular genetic investigation. Classifications of these
patients were: female pre-mutation, male pre-mutation, male full mutation and
female full mutation (2). Lymphoblastoid cell lines were established after EBV
transformation, ensuring continued future supply. Each cell line was tested for
Hepatitis A, Hepatitis B, Hepatitis C, Parvovirus B19 and HIV1. Master and
working cell banks were established and stored to ensure continual future
supplies of the same cells. Safety of storage was guaranteed by distribution to
multiple liquid nitrogen vessels at multiple locations. Cell banks were identity-
tested by DNA profiling with the Applied Biosystems 11-locus SGM+ kit.
FMR1 (CCG)n repeat genotypes of the cell lines were confirmed to match those
of the donor patients, except for the two female full mutation cell lines that
remained unconfirmed before the collaborative study. For that reason, two
female full mutation samples were included in the panel for the collaborative
study, in case one proved more suitable than the other for use as an RM.
DNA extraction and freeze drying
Cells were bulk cultured (ECACC, Porton Down, UK) to approximately 1010
cells and frozen as pellets of 108 cells. Genomic DNA was extracted from cell
pellets using the PureGene DNA purification and Autopure LS equipment
(Qiagen, Crawley, UK). The integrity of the extracted DNA was confirmed by
electrophoresis in agarose gels. Each of the DNA samples was dissolved at a
concentration of approximately 29mg/ml in 0.8mM Tris/0.08mM EDTA buffer
with 2.5mg/ml Trehalose. A volume of 0.8ml of this solution was dispensed
into a minimum of 1200 glass ampoules and freeze-dried. Sealed ampoules
were stored at 20 1C.
Homogeneity testing
Samples were tested for homogeneity by determining DNA concentration by
spectrophotometric absorbance analysis (Nanodrop, Wilmington, DE, USA).
After reconstitution in distilled water, the samples were allowed to equilibrate
to room temperature and mixed through pipetting after 30min. Samples were
quantitated after 1 h. The accuracy and precision of the spectrophotometer
were determined by performing multiple reads on a control sample of
commercial genomic DNA (Promega, Southampton, UK).
Accelerated degradation study
Ampoules were tested for degradation by agarose gel and quantitative PCR
comparison of samples stored at +56 and 20 1C with samples stored at
150 1C. For agarose gel electrophoresis, the size marker was Hyper Ladder VI
(Bioline, London, UK). For Q-PCR, the PCR primer sequences (5¢–3¢),
forward: 5¢-TTACAAGCCTGATGAAGGGA-3¢ and reverse: 5¢-CCATGAATAG
CACTGGGAGCATTGAAGC-3¢, were used at 10mM to amplify a 486-bp
sequence of F2 on chromosome 11. Cycling conditions were 95 1C for
10min, then 45 cycles of 95 1C for 10 s, 60 1C for 20 s and 72 1C for 30 s using
the LightCycler FastStart DNA Master plus SYBR Green I kit on a LightCycler
480 thermal cycler (Roche, Burgess Hill, UK).
Methylation analysis
For analysis of methylation status at the FMR1 promoter, Methyl Primer
Express v1.0 was used to design bisulphite-specific sequence primers for the
amplification of a 192-bp region, covering 22 CpGs, of the FMR1 gene
promoter region (position 3435241–3437401 of NT_011681 of Chromosome
X, NC_000023), upstream of the CGG repeat region. Primers used were
forward 5¢-TTACAAGCCTGATGAAGGGA-3¢ and reverse 5¢-CCATGAATAGC
ACTGGGAGCATTGAAGC-3¢. Ampoules were reconstituted in 40ml water and
left to reconstitute for 60min. Approximately 50ng of bisulphite-converted
DNA was used in the final HRM reaction mix, containing 1U Hot Star Taq
(Qiagen), 3mM MgCl2, 5 pmol primers, 200mM dNTPs and 5mM Syto9. PCR
was performed on the Rotorgene 6000, and consisted of an initial 10min
denaturation step at 95 1C, followed by 40 cycles of 30 s at 95 1C, 30 s at 55 1C
and 45 s at 72 1C with a final 7min extension at 721C. This PCR was followed
by a melting step for HRM, which consisted of 95 1C for 5 s, followed by 50 1C
for 5min and a temperature ramping from 70 to 95 1C at a rate of 0.2 1C/s.
Fluorescence was acquired on the HRM channel. HRM data were analysed
using Rotorgene 6000 software. The leading and trailing edges were normalized
at 72–74 and 83–86 1C, respectively. The assay was performed on three
ampoules of each sample.
Collaborative validation study
Each of the six gDNA materials was sent in triplicate and blinded to each
laboratory with instructions for reconstitution and storage. Each laboratory
was asked to perform their routine test(s) for Fragile X syndrome on each of the
18 coded samples and to genotype the samples in groups of six on three
separate days as indicated on the results sheet, using different lots of reagents or
different operators if possible. Laboratories were asked to report the number of
trinucleotide repeats. The overall findings for each sample and raw data, eg-
images of autoradiographs, were to be returned together with full details of
techniques used, any in-house or commercial controls and reasons for failure of
any of the samples tested.
RESULTS
Each cell line was found to be negative for Hepatitis A, Hepatitis B,
Hepatitis C, Parvovirus B19 and HIV1. All EBV-transformed cell lines
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remain positive for the presence of the EBV genome. Whereas there is
an unquantified risk of EBV infectivity in the cell lines, infective viral
particles are unlikely to survive DNA extraction and have not been
detected in electron microscopy studies or in infectivity assays (JRH,
unpublished data). In all cases cell line DNA profiles matched the
profile of the original blood samples. No samples showed evidence of
cross-contamination. However, sample 07/174 showed a very small
additional peak at just two short tandem repeat marker loci. These
peaks were not detected in the original blood samples.
Bulk genomic DNA was filled into glass ampoules, freeze-dried and
sealed. Upon reconstitution with 40ml sterile water the DNA concen-
tration was approximately 580mg/ml in 16mM Tris, 1.6mM EDTA and
50mg/ml Trehalose. The pH of the reconstituted candidate materials
was measured and was found to be within 7.4 and 7.8 in all six. Table 1
shows the product summary for the six materials. Residual moisture
and oxygen levels were consistent with those obtained in previous fills
and within the levels acceptable for International Standards by the
WHO.18
Homogeneity
Random ampoules were weighed periodically during the ampoule
filling of each material. The coefficient of variation for each fill
(0.15–0.31%; Table 1) indicates a very low level of variation in
volumes aliquotted during each fill run.
The materials were tested for DNA homogeneity after reconstitu-
tion both within ampoules and between ampoules by DNA quantita-
tion. Ten randomly selected ampoules of each material were
reconstituted in 40ml distilled water. The DNA concentration of
each ampoule was measured in triplicate. The triplicate reads were
highly consistent, giving a modal coefficient of variability of just 2.9%.
The distribution of variability is shown in Figure 1a. These data
indicate that the material in the ampoules is highly homogeneous 1 h
after reconstitution.
DNA concentrations showed more variation between individual
ampoules of each material and between the different materials
(Figure 1). However, the intended purpose is independent of DNA
concentration above a minimum level and the amount supplied
in each ampoule is enough for several tests by Southern blotting.
Mean concentrations of each material varied from 568 to 818mg/ml,
equating to a mean of at least 23mg per ampoule. Coefficients of
variability between ampoules of a single material ranged from 7.2 to
15.3%.
Stability
An accelerated degradation study on samples stored at +56 1C was
carried out. When compared with samples stored at 150 1C, after
2-years storage there was no detectable degradation in samples 07/122,
07/168, 07/170 or 07/174 as assessed by Q-PCR (Figure 2a). Ampoule
07/120 showed an increase in Cp value of 0.54 between the 150 and
+56 1C samples, indicating a 31% decrease in DNA yield. This
difference, however, may be the result of ampoule-to-ampoule varia-
bility or due to a ‘baking’ effect resulting in incomplete solubilization.
The Q-PCR findings were confirmed by agarose gel electrophoresis,
where there was a slight increase in band mobility for the +56 1C
Table 1 Ampoule product summaries of the six candidate materials
NIBSC code 07/120 Female,
wild type
07/122 Female,
pre-mutation
07/168 Female,
full mutation 1
07/170 Male,
full mutation
07/172 Female,
full mutation 2
07/174 Male,
pre-mutation
Date filled 19.04.07 26.04.07 07.06.07 08.06.07 14.06.07 21.06.07
Coefficient of variation of the fill (%) (n¼39–44) 0.31 0.15 0.20 0.16 0.25 0.24
Residual moisture after lyophilization (%) (n¼12) 3.62 3.127 1.145 1.443 0.618 0.823
Mean dry weight (g) (n¼6) 0.0025 0.0022 0.0019 0.0020 0.0021 0.0024
Residual oxygen (%) (n¼12) 0.41 0.61 0.27 0.29 0.16 0.59
Mean OD ratio 260/280 nm (n¼6) 1.85 1.79 1.88 1.83 1.86 1.89
Mean DNA conc. following resuspension in
40ml water ng/ml (n¼6)
573.4 488.0 581.4 502.1 576.0 740.4
pH following resuspension 7.4 7.6 7.4 7.5 7.8 7.4
No of ampoules available 1728 2132 1758 2061 1774 1211
Presentation Sealed, glass DIN ampoules
Excipient Trehalose 2.5mg/ml in Tris/EDTA buffer
Storage temperature 20 1C
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Figure 1 Homogeneity. (a) Variability (% CV) in triplicate DNA quantitation
reads from 10 ampoules of each material. The modal CV of reads from a
single ampoule is 2.9%, indicating the material is highly homogeneous within
ampoules. (b) Variability between fills and between ampoules. Columns show
mean DNA concentration (mg/ml) from 10 ampoules from each fill. Error bars
show DNA concentration variability (±1 SD) between ampoules.
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sample as well as a slight decrease in band intensity, but no visible
increase in low molecular weight DNA (Figure 2b). Densitometry
analysis of the gel bands indicates an average signal reduction of 22%
for the +56 1C samples. Together, the Q-PCR and electrophoresis data
indicate some, but limited degradation at +56 1C. However, the
limited degradation at +56 1C and the absence of degradation at the
storage temperature of 20 1C after 2 years indicate that the DNA
should be stable for many years.
Validation
To validate that the materials are fit for purpose as RMs in the
laboratory diagnosis of Fragile X syndrome, laboratories were invited
to participate in an international collaborative study. In all, 38
laboratories were invited to take part in the study, 23 laboratories
agreed to participate and results were returned by 21 laboratories.
Seventeen different countries were represented among participants
who returned the results: 13 from Europe, 4 from North America, 3
from Australasia and 1 from Asia. Collaborative validation study
participants were requested to test the 18 coded samples on three
separate days using different lots of reagents or different operators if
possible. The methods used by the participants are listed in Table 2.
Seventeen laboratories used in-house assays and four laboratories used
a commercial kit developed by Celera and available from Abbott
Molecular (Des Plaines, IL, USA). Some laboratories usually refer
selected samples to another laboratory to complete their investigation
(laboratories 11 and 15) and others were unable to carry out their
usual testing protocol because of technical difficulties (laboratories 8,
14 and 19). Laboratory 14 could not obtain any useful Southern
blotting results with the samples supplied, whereas their in-house
controls gave the expected results, as did the study samples in their
PCR test.
No two in-house methods were entirely identical. Some laboratories
indicated that their method was based on a previous publication (see
Supplementary Data). Eight laboratories were able to use more than
one batch of reagents and the testing was carried out by more than
one operator in five laboratories. There is no evidence of the study
materials performing differently between different methods. The
materials performed similarly to patient samples in Southern blotting,
with a spread of bands from expanded alleles, although none of the
spreads were as extreme as can be seen in some patient samples
(Figure 3a). The methylation states of the alleles are indicated in
Figure 3b. The normal female and female pre-mutation samples gave a
two-peak melting profile, with the larger peak indicating unmethyl-
ated and the smaller peak indicating methylated. This melting profile
corresponds with the two alleles present in these samples, one of which
is X-inactivated and appears as the higher Tm methylated peak. The
female full mutation-1 sample also gave the two-peak melting profile,
which indicates that the FMR1 expansion lies largely on the inacti-
vated X-chromosome. In contrast, the female full mutation-2 sample
gave a single methylated melting peak profile, indicating that the
FMR1 expansion lies largely on the active X-chromosome. Male
samples, however, have a simpler melting profile as they possess
only a single X allele. The male pre-mutation sample gave a single
low Tm peak, indicating that the Fragile X promoter is unmethylated.
The male full mutation sample shows a single fully methylated peak,
indicating the presence of only a fully methylated Fragile X promoter.
The controls used by participants were as follows: 17 laboratories
used in-house materials (previously characterized clinical samples
from patients and normal controls), 6 laboratories used DNA samples
supplied by the Coriell Institute and 1 lab used NIST PCR product
controls.
Tables listing the full genotyping results of the validation study
are available as Supplementary Data. Summaries of the clinical inter-
pretations are as follows: samples 1, 11 and 12 (normal female): 19
labs reported ‘normal female’ (or ‘normal genotype’). Exceptions to
this interpretation were: lab 11 did not get a PCR product with one
out of the three samples, and reported normal female for the other
two samples. lab 19 obtained genotypes in all three samples but was
unable to complete the investigation and made no interpretation.
Samples 2, 7 and 14 (female, pre-mutation): 16 labs reported ‘female,
pre-mutation’. Exceptions to this interpretation were: lab 14, which
detected the pre-mutation in only one out of three samples and was
unable to make an interpretation for two samples; lab 11 would refer
all three samples for Southern blotting; labs 15 and 17 reported all
three samples as ‘normal female’; lab 19 obtained genotypes in all
three samples but was unable to complete the investigation and made
no interpretation. Samples 3, 8 and 17 (female, full mutation): 14 labs
Accelerated degradation- Real-Time PCR 
Material Storage Temperature
-150°C -20°C +56°C
Cp CV% Cp CV% Cp CV%
07/120 (normal female) 20.51 0.11 20.71 0.20 21.05 0.07
21.23 0.03 20.57 0.10 20.80 0.13
20.97 0.06 20.61 0.13 20.77 0.36
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N/D N/D N/D
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Figure 2 Accelerated degradation. (a) Accelerated degradation – real-time
PCR. Crossing point (Cp) values for quantitative PCR (Roche Lightcycler)
after storage of ampoules at baseline (150 1C) and elevated temperatures
for 2 years. CVs show the level of variability between triplicate runs.
(b) Accelerated degradation – agarose gel. 0.7% agarose gel of 200ng of
each sample. The size marker is Hyperladder VI (Bioline).
Table 2 Testing procedure used by the participants
Testing procedure Participant laboratory code number
In-house assays Abbott kit
PCR, then Southern blotting if required 4, 8, 17
Southern blotting, then PCR if required 1
All samples PCR and Southern blotting 6, 7, 9, 10, 12, 13,
14, 18, 20
3
PCR only 11, 15, 19 2, 5, 16
PCR and DNA sequencing 21
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reported ‘female full mutation’. Exceptions to this interpretation were:
lab 16 reported ‘female full mutation’ with only two out of three
samples and would refer the third sample for Southern blotting; labs
11, 14 and 15 would refer all samples for Southern blotting; lab 17
reported a different result for all three samples (normal male, male or
Turner’s syndrome, female full mutation); lab 19 only tested two
samples and obtained genotypes but was unable to complete the
investigation and made no interpretation; Lab 21 reported only ‘one
allele detected by PCR’ and made no clinical interpretation. Samples 4,
10 and 18 (male full mutation): 14 labs reported ‘male full mutation’.
Exceptions to this interpretation were: labs 11, 15 and 16 suspected a
full mutation and would refer all samples for Southern blotting; lab 8
reported ‘normal male’ with all three samples; lab 17 reported ‘male
pre-mutation’ with two out of three samples and ‘male full mutation’
with the third sample; lab 19 was unable to complete the investigation
and made no interpretation. Lab 21 did not amplify a PCR product
and made no interpretation. Samples 5, 15 and 16 (female, full
mutation): 14 labs reported ‘female full mutation’. Exceptions to this
interpretation were: lab 8 suspected a full mutation but was unable to
obtain Southern blot data; labs 11, 14 and 15 would refer all samples
for Southern blotting; lab 17 reported ‘normal female’ with two out of
three samples and ‘female full mutation for the third sample; lab 19
was unable to complete the investigation and made no interpretation;
lab 21 reported only ‘one allele detected by PCR’. Samples 6, 9 and 13
- 754
- 510
- 346
- 113/114
Normal Female
(07/120)
Female premutation
(07/122)
Female full mutation 1
(07/168)
Female full mutation 2
(07/172)
Male premutation
(07/174)
Male full mutation
(07/170)
Figure 3 Southern blot of study samples. (a) Southern blot of study samples showing male and female; normal, pre-mutation and full expansion banding
patterns. The control samples are patient DNA samples extracted from blood. Consensus expanded triplet repeat numbers are indicated on the right.
(b) High-resolution melt analysis. The x-axis represents temperature from 70 to 95 1C. The y-axis represents dF/dT (difference in fluorescence over
temperature) from zero to 1.4. Methylation status is indicated by the presence and relative size of the left peak (unmethylated) and the right peak
(methylated). The melt curves for the three ampoules used for each sample are presented in different colours.
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(male, pre-mutation): 17 labs reported ‘male pre-mutation’. Excep-
tions to this interpretation were: labs 11 and 15 suspected a pre-
mutation and would refer all samples for Southern blotting; lab 17
reported ‘normal male’ for two samples and ‘male full mutation’ for
the third sample; lab 19 was unable to complete the investigation and
made no interpretation.
A total of 18 non-consensus results were reported, giving an overall
rate of non-concordance of 4.9% (21 laboratories  18 samples – 7
samples not tested), although these were clustered in three labora-
tories. There was no correlation between the non-concordant results
and any particular sample or a specific method. One laboratory
reported 12 of the 18 non-concordant results. This laboratory was
contacted, and their testing protocol was changed.
Genotyping results are presented in Figure 4. The sample testing
mean allele sizes and ranges obtained are summarized in Table 3.
Three outliers identified by Grubbs’ Test were omitted from the data
analysis.19 These were: female full mutation 1 – allele 2: 575 repeats;
female full mutation 2 – allele 1: 26 repeats; male full mutation – 7
repeats.
The detection of a very small 7 repeat allele in the male full
mutation samples by two laboratories was unexpected. Such minimal
repeats are occasionally detected in full mutation clinical samples and
it is unclear if the small repeat is an assay artifact or a true mosaic
allele. In this study, one laboratory (lab 8) found the seven repeats by
PCR and interpreted the result as a normal male without carrying out
Southern blotting, whereas the other laboratory (lab 18) found a
similar peak by PCR but noted it as a likely artifact and continued to
identify a full expansion by Southern blotting.
DISCUSSION
In the absence of RMs, genetic tests are being performed without
adequate controls and new assays are difficult to validate. The need for
RMs in Fragile X syndrome testing is particularly pressing, as it is a
technically challenging test. For use in in vitro diagnostic assays, RMs
in the EU must be CE-marked or in the United States must be FDA-
approved. Alternatively, according to the EU IVD directive (Directive
98/79/EC of the European Parliament and of the Council of 27 October
1998 on in vitro diagnostic medical devices), RMs of ‘higher order’ are
exempted from CE marking. WHO international standards are
accepted as internationally recognized ‘highest order’ measurement
standards.
Although aimed to promote the wider availability and safety of
commercial products for in vitro diagnostics, the European IVD
directive may have hampered RM development and use by preventing
the distribution of ‘in-house’ quality control samples between labora-
tories. This also hampers harmonization of quality between labora-
tories. Despite the existence of a PCR-product-based certified RM for
Fragile X testing (NIST, USA), there was a need for a more commutable,
that is, cellular or genomic, certified RM. As EBV-positive cell lines
are classified as requiring handling in Category 2 facilities and their
shipment must be handled as ‘infectious’, the use of EBV-established cell
lines as RMs is not practical. We therefore chose to produce a panel
of genomic DNAs derived from cell lines, which could be certified as
a ‘higher order’ RM panel. Purified genomic DNA was freeze-dried
in glass ampoules. Twenty-one laboratories from seventeen countries
collaborated in a validation study of the panel of proposed RMs.
Analysis of material homogeneity showed a significant level of
variability between fills and between ampoules. Reasons for this are
not clear. That the source of the variation is not due to the spectro-
photometer is demonstrated by the low level of variability within
ampoules and within the control sample reads (n¼10; %CV¼1.84).
Variation in DNA concentration between fills may be due to inaccu-
rate quantitation before ampoule filling, or due to poor homogeneity
of the bulk DNA before filling. Variation between ampoules of the
same fill may also be due to poor homogeneity of the bulk DNA. It is
difficult to achieve complete homogeneity in solution while retaining
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Figure 4 Distribution of allele repeat numbers reported by study
participants. The graphs show the number of laboratories (y-axis) detecting
each allele length (x-axis). The number of repeats was calculated for each
sample in all laboratories, where possible, by taking a mean of all three
replicates of the same sample tested in one or more techniques. Where
a range of repeats was given the mean value was used. Values reported
with ‘greater than’ or ‘less than’ symbols (4, o) were omitted. Where an
approximate size was given, this was taken as definitive. All values have
been rounded up to whole numbers for clarity. Sample outliers as identified
by Grubbs’ Test have been omitted.
Table 3 Summary of allele sizes and ranges
Allele 1 Allele 2
Mean Range Mean Range
Normal female 22 19–24 31 28–33
Female pre-mutation 33 30–36 113 100–132
Male pre-mutation 114 97–127
Female full mutation 1 38 33–41 346 300–401
Female full mutation 2 19 17–21 510 355–600
Male full mutation 754 353–960
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the high-molecular-weight DNA required for this application. Because
of this variability, users are requested to determine the DNA concen-
tration of each ampoule themselves. The high level of homogeneity
within the reconstituted ampoules, however, means that the user can
be confident that the sample concentrations will not significantly vary
between aliquots from a single ampoule.
Analysis of material stability by Q-PCR and gel electrophoresis of
accelerated degradation samples shows some degradation at +56 1C
after 2 years. However, the limited extent of degradation at elevated
temperature and the absence of degradation at the storage tempera-
ture of –20 1C after 2 years indicates that the DNA should be stable
for many years. Further samples stored at these temperatures as well
as others stored at intermediate temperatures will be monitored at
regular intervals in the future as part of planned quality control
testing.
DNA profiling of the materials showed very small additional peaks
at two loci in one sample (07/174). These peaks were not detected in
the original blood samples. That the participants of the collaborative
study did not obtain any anomalous results specific to this material
and the lack of additional peaks at other loci suggest that these very
minor peaks are caused by microsatellite mosaicism rather than
contamination.
The wide spread of allele sizes obtained in the collaborative
validation study is typical of that obtained in Fragile X testing external
quality assessment schemes. A total of 18 incorrect results was
reported, giving an overall error rate of 4.9%. This error rate is similar
to the 5% level found in an Italian 5-year quality assessment,7 but
higher than that observed in our previous studies with different panels
(Factor V Leiden: 0.7%; Prothrombin mutation G20210A: 0.7%;
Haemophilia A Intron 22 Inversion: 1.8%)20 (also, EG, unpublished
data). The high variability of the results, both in reported repeat
numbers and the interpretation of results, emphasizes the difficulty of
FMR1 repeat sizing and the need for Fragile X syndrome RMs. The
finding by two laboratories of an unexpected 7-repeat PCR product is
a concern. It is unclear if this small additional putative allele is
representative of the clinical sample from which it was derived or is
a cell culture or typing artifact. To avoid confusion in the use of this
sample as an RM, a caution on the possibility of detecting this putative
allele is included in the ‘Instructions for Use’ for the panel. Although
the presence of this allele makes the sample unsuitable for use in
external quality assessment, it does not detract from the sample’s
utility as an RM, once the user is aware of it.
By producing the reference panel from a single large batch of
pooled DNA derived from a single bulk cell culture batch, the need to
repeatedly re-culture the cells for the production of multiple small
batches is avoided. This is important as new size alleles can be
generated over time in cell culture, particularly when allelic methyla-
tion is only partial. It is therefore possible that if this RM batch is ever
exhausted, the genotype of the replacement batch may not be
identical. However, at that stage a repeat collaborative validation
study would be performed to characterize the materials fully.
Two female full mutation samples were included in the study as
neither had been previously genotyped and demonstrated to be
suitable for inclusion in a reference panel. Both samples performed
well. To maintain the widest variety of allele sizes, sample 1 (07/168)
was included in the reference panel of five samples (normal female,
female pre-mutation, male pre-mutation, female full mutation, male
full mutation).
All laboratories that participated in the collaborative study were
sent a study report and their approval was sought. All laboratories
agreed that the candidate material is suitable for use as a genetic
reference panel for Fragile X syndrome. The most frequent comment
from the participants (n¼6) was that the DNA was of good quality.
Three laboratories reported that the DNA concentration varied more
than expected and two laboratories did not like the glass ampoules.
The report was then endorsed by the board of the European
Society for Human Genetics and was finally submitted to the
Expert Committee on Biological Standardization at the World Health
Organization (WHO). In November 2008, the panel was established
as a WHO International Standard and made available through the
NIBSC product catalogue (http://www.nibsc.ac.uk/products/catalogue.
html) - code: 08/158.
The panel is the only certified set of genomic DNA RMs for Fragile
X testing and is available to all diagnostic laboratories worldwide to
aid accuracy in Fragile X syndrome testing. The panel will be of
particular importance for the validation of commercial diagnostic kits
for Fragile X syndrome that are beginning to enter the market, for
laboratories setting up new in-house methods such as methylation
analysis and for validating existing techniques after a change of
reagents, operator or equipment.
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